Amgen (AMGN) Prepaid Assets (2009 - 2026)
Amgen (AMGN) posted quarterly Prepaid Assets of $4.1 billion for Q1 2026, up 26.24% year-over-year from $3.3 billion in Q1 2025, and little changed on a QoQ basis from $4.1 billion in Q4 2025.
Amgen (AMGN) Prepaid Assets (2009 - 2026) Analysis & Trends
Amgen (AMGN) has reported Prepaid Assets for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 26.24% year-over-year to $4.1 billion; the TTM figure through Mar 2026 stood at $4.1 billion (up 26.24% YoY), while the FY2025 annual figure was $4.1 billion, up 26.12% from the prior year.
- Prepaid Assets came in at $4.1 billion for Q1 2026 at Amgen, roughly flat from $4.1 billion in the prior quarter.
- The five-year high for Prepaid Assets was $4.1 billion in Q4 2025, with the low at $2.3 billion in Q2 2022.
- Average Prepaid Assets over 5 years is $3.0 billion, with a median of $2.8 billion recorded in 2024.
- Across the five-year window, Prepaid Assets fell 6.81% in 2022 and climbed 28.06% in 2024, its largest moves.
- Year by year, Prepaid Assets stood at $2.4 billion in 2022, then rose by 8.96% to $2.6 billion in 2023, then increased by 25.94% to $3.3 billion in 2024, then rose by 26.12% to $4.1 billion in 2025, then declined by 0.48% to $4.1 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.1 billion, $4.1 billion, and $3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.11 Bn |
| Dec 31, 2025 | 4.13 Bn |
| Sep 30, 2025 | 3.60 Bn |
| Jun 30, 2025 | 3.42 Bn |
| Mar 31, 2025 | 3.26 Bn |
| Dec 31, 2024 | 3.28 Bn |
| Sep 30, 2024 | 3.08 Bn |
| Jun 30, 2024 | 2.98 Bn |
| Mar 31, 2024 | 2.82 Bn |
| Dec 31, 2023 | 2.60 Bn |
| Sep 30, 2023 | 2.57 Bn |
| Jun 30, 2023 | 2.32 Bn |
| Mar 31, 2023 | 2.40 Bn |
| Dec 31, 2022 | 2.39 Bn |
| Sep 30, 2022 | 2.50 Bn |
| Jun 30, 2022 | 2.26 Bn |
| Mar 31, 2022 | 2.49 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 2.54 Bn |
| Jun 30, 2021 | 2.42 Bn |